Insulet Corporation

Insulet Corporation's CEO and two directors made significant insider stock purchases in 2026, even as the company faced a voluntary medical device correction for certain Omnipod pods. CEO Ashley McEvoy bought 4,300 shares in late February at an average price of $239.35, investing just over $1 million, while independent director Michael Minogue purchased 2,030 shares at $246.23, totaling about $499,800. Independent chair Elizabeth Weatherman bought roughly $497,000 worth of stock in early June at $144 per share, boosting her holdings by 66%. The company initiated a voluntary correction on May 26 for specific lots of Omnipod 5, Dash, and Eros pods due to a cannula tear that could cause insulin under-delivery, sending shares down over 5% to around $146. Insulet shares closed at $161.28 on August 12, down 11.78% over one month and 54.06% over 52 weeks, with a market capitalization of $11.17 billion.

JPMorgan downgraded insulin pump maker Insulet to Neutral from Overweight and slashed its price target to $152 from $275, citing slowing U.S. sales growth, rising attrition among Type 2 diabetes patients, and a weaker-than-expected outlook for 2027. The brokerage removed the stock from its Analyst Focus List, arguing that decelerating new patient additions, higher Type 2 patient attrition, and looming competition in the patch pump market could weigh on growth. JPMorgan lowered its 2027 revenue forecast by 7.6% to $3.67 billion and cut its adjusted EPS estimate by 8.8% to $7.62, while making only modest changes to its 2026 forecasts. The firm said management's early commentary for 2027 appeared too optimistic and expects investors to remain cautious until growth stabilizes and earnings expectations are reset. International performance remained solid, supported by strong Omnipod adoption and expansion into markets such as Spain and Australia, but JPMorgan believes those positives are likely to be overshadowed by slowing U.S. growth and intensifying competition expected to emerge in 2027.

Insulet has updated its full-year 2026 revenue growth outlook to 20% to 22%, down from its prior forecast, citing lower-than-expected utilization and retention among type 2 diabetes customers in the U.S. The company reported second-quarter revenue of $802 million, beating analyst estimates, with adjusted earnings per share of $1.66. CEO Ashley McEvoy described the type 2 trends as an execution challenge, noting that more than 40% of new U.S. customer starts are people with type 2 diabetes but that retention and utilization rates have weakened. In response, Insulet is expanding its customer care team, changing sales force compensation to reward longer-term retention, refining sample deployment, and rolling out new technology platforms. The updated guidance assumes these type 2 trends persist through the second half of the year, with U.S. Omnipod revenue growth now seen at 17% to 19% and international revenue growth at 30% to 32%.

The Law Offices of Howard G. Smith reminds investors of upcoming lead plaintiff deadlines in securities fraud class actions against Insulet Corporation, Microvast Holdings, and Hub Group. For Insulet, the class period is February 21, 2025 to May 26, 2026, with a lead plaintiff deadline of August 31, 2026; the complaint alleges defective manufacturing controls and misleading statements. For Microvast, the class period is April 1, 2025 to March 16, 2026, with a deadline of September 21, 2026; the complaint alleges overstated margin targets and delays in the Huzhou Phase 3.2 expansion. For Hub Group, the class period is April 28, 2023 to May 11, 2026, with a deadline of August 28, 2026; the complaint alleges material misstatements in financial statements from Q1 2023 to Q3 2025. Investors who suffered losses may contact the firm to discuss their legal rights.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Futu Holdings, Hub Group, Insulet Corporation, and Photronics. For Futu Holdings, the lead plaintiff deadline is August 25, 2026, with allegations that the company failed to disclose non-compliance with CSRC requirements and overstated financial results. Hub Group faces an August 28, 2026 deadline over claims of material misstatements in financial statements from Q1 2023 to Q3 2025. Insulet Corporation has an August 31, 2026 deadline, with allegations of defective manufacturing controls and safety regulation violations. Photronics has a September 4, 2026 deadline, with claims that the company failed to disclose severe bottlenecks in its high-end chip design release pipeline.

SueWallSt reminds Insulet Corporation investors that the lead plaintiff deadline for a pending securities class action is August 31, 2026. The lawsuit covers shareholders who purchased Insulet securities between February 21, 2025 and May 26, 2026, alleging the company made misleading statements about its manufacturing quality and product safety. Insulet's stock fell from approximately $236 to $146.01 after two Medical Device Corrections disclosed in March and May 2026, with the second affecting roughly 7 million Omnipod Pods across multiple product lines. The complaint also alleges that insiders sold $5.9 million in stock during the class period. Investors may contact SueWallSt, powered by Levi & Korsinsky LLP, for a no-cost case evaluation.

Rosen Law Firm reminds purchasers of Insulet Corporation securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Insulet made false and misleading statements about its manufacturing controls and procedures, which created a risk of product safety violations and investor damages when the truth emerged. Investors may be entitled to compensation through a contingency fee arrangement and can join the action by contacting the firm. Rosen Law Firm highlights its track record in securities class actions, including the largest-ever settlement against a Chinese company and over $438 million recovered for investors in 2019.

Rosen Law Firm reminds purchasers of Insulet Corporation securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Insulet made false or misleading statements and failed to disclose defective manufacturing controls and procedures, which created a risk that products would violate safety regulations or cause injury. Investors who purchased Insulet securities during the class period may be entitled to compensation through a contingency fee arrangement. Rosen Law Firm highlights its track record in securities class actions, including achieving the largest ever settlement against a Chinese company and recovering billions of dollars for investors.

A securities fraud class action has been filed against Insulet Corporation and certain senior executives, with a lead plaintiff deadline of August 31, 2026. The lawsuit, pending in the U.S. District Court for the District of Massachusetts, alleges that Insulet misrepresented the safety of its Omnipod insulin delivery products and its manufacturing quality. On March 12, 2026, the company disclosed a manufacturing defect causing insulin under-delivery, triggering a 6.88% stock drop from $236.07 to $219.84 per share. A second correction on May 26, 2026, covering Omnipod 5, Omnipod DASH, and Omnipod Eros systems, led to a further 5.07% decline from $218.11 to $146.01 per share. Investors who suffered losses are encouraged to contact Bleichmar Fonti & Auld LLP before the deadline to seek lead plaintiff appointment.

A securities fraud class action lawsuit has been filed against Insulet Corporation on behalf of investors who purchased securities between February 21, 2025 and May 26, 2026. The lawsuit alleges that Insulet made misleading statements by failing to disclose defective manufacturing controls and procedures, which created a heightened risk of product safety violations. On March 12, 2026, the company announced a voluntary Medical Device Correction for certain Omnipod 5 Pods, causing shares to fall 7% from $236.07 to $219.84. Then on May 26, 2026, another correction was disclosed for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods due to a manufacturing issue that could cause insulin under-delivery, leading to a 5% drop from $153.80 to $146.01. Investors have until August 31, 2026 to seek lead plaintiff appointment through Kirby McInerney LLP.

A class action lawsuit has been filed against Insulet Corporation for securities fraud related to the safety of its Omnipod insulin delivery products. The suit, pending in the U.S. District Court for the District of Massachusetts, alleges that Insulet misrepresented product safety and its manufacturing quality, concealing defects that risked patient health. On March 12, 2026, the company disclosed a manufacturing issue causing tears in the internal tubing of Omnipod 5 Pods, leading to a 6.88% stock drop from $236.07 to $219.84 per share. A second correction on May 26, 2026, affecting Omnipod 5, Omnipod DASH, and Omnipod Eros systems, triggered a further 5.07% decline from $218.11 to $146.01 per share. Investors have until August 31, 2026 to seek lead plaintiff appointment.

The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Futu Holdings Limited, Hub Group, Inc., Insulet Corporation, and Photronics, Inc., with lead plaintiff deadlines ranging from August 25 to September 4, 2026. The complaint against Futu alleges the company made false or misleading statements by failing to disclose non-compliance with CSRC requirements, including conducting securities, public fund sales, and futures business in mainland China without proper licenses, which could lead to regulatory penalties and overstated financial results. Hub Group is accused of material misstatements in financial statements from Q1 2023 to Q3 2025 due to premature transaction recognition and understated costs. Insulet allegedly had defective manufacturing controls that created a risk of safety violations, while Photronics is said to have concealed severe bottlenecks in its high-end chip design release pipeline. Investors who suffered losses may contact the firm to discuss their legal rights.

Grabar Law Office is investigating potential fiduciary duty breaches by officers and directors of Erasca, Insulet, Photronics, and Via Transportation. The Erasca probe concerns disclosures about its pan-RAS molecular glue candidate ERAS-0015, including alleged improper comparisons to Revolution Medicines' RMC-6236 and undisclosed intellectual property risks; on April 27, 2026, the company disclosed patent infringement allegations and preliminary Phase 1 data showing a patient death, after which its share price fell substantially. The Insulet investigation relates to manufacturing defects that led to voluntary Medical Device Corrections for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods on March 12 and May 26, 2026, due to a risk of insulin under-delivery. Photronics is being investigated over statements about strong demand for high-end IC photomask products that allegedly omitted stalled customer design releases caused by foundry utilization and cost pressures. The Via Transportation probe focuses on its September 15, 2025 IPO, with allegations that offering documents failed to disclose declining Platform Annual Run-Rate Revenue per customer and regulatory hurdles in Germany. Current long-term shareholders of each company may seek corporate governance reforms and damages through shareholder derivative actions at no personal cost.

Rosen Law Firm reminds purchasers of Insulet Corporation securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Insulet made false and misleading statements and failed to disclose defective manufacturing controls and procedures, which created a heightened risk of safety violations or injury. Investors who purchased Insulet securities during the class period may be entitled to compensation through a contingency fee arrangement. Rosen Law Firm highlights its track record in securities class actions, including the largest-ever settlement against a Chinese company and over $438 million recovered for investors in 2019 alone.

Holzer and Holzer LLC reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against Insulet Corporation, Photronics Inc., and Planet Fitness Inc. The deadline for Insulet is August 31, 2026, for a case alleging misleading statements about manufacturing controls and procedures between February 21, 2025 and May 26, 2026. The deadline for Photronics is September 4, 2026, for a case alleging misleading statements about its high-end product pipeline and demand stability between December 10, 2025 and May 27, 2026. The deadline for Planet Fitness is September 14, 2026, for a case alleging misleading statements about its Black Card price increase rollout, membership growth, and marketing strategy between November 6, 2025 and May 6, 2026. Investors who purchased shares during the respective periods and suffered losses are encouraged to contact the firm.

Glancy Prongay Wolke & Rotter LLP reminds Insulet Corporation investors that the deadline to file a lead plaintiff motion in a securities fraud class action is August 31, 2026. The lawsuit covers investors who purchased or acquired Insulet securities between February 21, 2025 and May 26, 2026. The complaint alleges that the company made false and misleading statements and failed to disclose defects in its manufacturing controls, which created a risk of product safety violations. Two voluntary medical device corrections for Omnipod pods were announced in March and May 2026, causing stock price drops of 6.9% and 5.1% respectively.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Futu Holdings, Hub Group, Insulet Corporation, and Photronics. For Futu Holdings, the lead plaintiff deadline is August 25, 2026, with allegations that the company failed to disclose non-compliance with CSRC requirements and overstated financial results. Hub Group faces an August 28, 2026 deadline over claims of material misstatements in financial statements from Q1 2023 to Q3 2025. Insulet Corporation has an August 31, 2026 deadline, with allegations of defective manufacturing controls that heightened the risk of safety violations. Photronics has a September 4, 2026 deadline, with claims that the company failed to disclose severe bottlenecks in its high-end chip design release pipeline.

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Insulet Corporation and certain officers, alleging violations of federal securities laws. The suit seeks to recover damages for investors who purchased or acquired Insulet securities between May 21, 2025 and May 26, 2026. The complaint claims that defendants made materially false and misleading statements regarding the company's business, operations, and compliance policies, including defective manufacturing controls that created a heightened risk of safety violations or injury. Investors have until August 31, 2026 to seek lead plaintiff appointment. The law firm represents investors on a contingency fee basis.

Pomerantz LLP has filed a class action lawsuit against Insulet Corporation and certain officers on behalf of investors who purchased Insulet securities between February 21, 2025 and May 26, 2026. The suit, filed in the US District Court for the District of Massachusetts, alleges that the company made false and misleading statements about its manufacturing controls and product safety. The complaint points to two voluntary medical device corrections disclosed in 2026—one on March 12 for Omnipod 5 Pods and another on May 26 for Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System Pods—which caused the stock to drop 6.88% and 5.07% respectively. Investors have until August 31, 2026 to seek appointment as lead plaintiff.

Insulet Corporation detracted from performance in the second quarter of 2026 amid broad medtech weakness, a minor product recall, quality issues, and rising concerns around potential future competition, according to ClearBridge Investments' SMID Cap Growth Strategy. The strategy noted that weakness in provider and select medical technology holdings offset otherwise solid contributions from biotechnology and life sciences tools. Insulet, known for its Omnipod insulin delivery system, saw its shares lose 44.77% over the past 52 weeks, closing at $161.28 on July 10, 2026. The company generated revenue of $762 million in the first quarter of 2026, an increase of 34% on a reported basis.

Faruqi & Faruqi, LLP reminds investors of the August 31, 2026 deadline to seek lead plaintiff in a securities class action against Insulet Corporation. The lawsuit alleges Insulet made false and misleading statements by failing to disclose defective manufacturing controls that created a heightened risk of product safety violations or injury. The truth began to emerge on March 12, 2026, when Insulet announced a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods, causing its stock to drop 6.88% to $219.84 per share. Then on May 26, 2026, Insulet disclosed another correction for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods due to a manufacturing issue that could cause insulin under-delivery, sending shares down 5.07% to $146.01. Investors who purchased Insulet securities between February 21, 2025 and May 26, 2026 may be eligible to participate.

The Schall Law Firm reminds investors of a class action lawsuit against Insulet Corporation for alleged securities fraud. The lawsuit covers investors who purchased Insulet securities between February 21, 2025 and May 26, 2026, with a lead plaintiff deadline of August 31, 2026. The complaint alleges Insulet made false and misleading statements about defective manufacturing controls and safety violations, and that a March 2026 Medical Device Correction impacted more Pod Products than disclosed. Investors who suffered losses are encouraged to contact the firm.

Grabar Law Office is investigating claims on behalf of long-term shareholders of First Solar, Insulet Corporation, Photronics, and Via Transportation. The investigations concern whether certain officers and directors of each company breached their fiduciary duties. For First Solar, the probe follows a securities fraud class action alleging executives overstated the company's ability to manage U.S. tariff policy impacts and understated negative effects on fiscal 2026 performance. For Insulet, a class action alleges defective manufacturing controls led to voluntary medical device corrections for Omnipod products in March and May 2026. For Photronics, a class action alleges the company made misleading statements about strong demand for high-end IC photomasks while knowing customer design releases had stalled. For Via Transportation, a class action alleges IPO offering documents omitted that the company was adding customers faster than they generated revenue and that regulatory issues would hinder its German expansion strategy. Shareholders who purchased shares before specified dates and still hold them can seek corporate reforms and return of funds at no cost.

Holzer and Holzer reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against Futu Holdings, Hub Group, and Insulet Corporation. The Futu lawsuit, covering purchases between May 24, 2023 and May 27, 2026, alleges misstatements about compliance with China Securities Regulatory Commission requirements, with a deadline of August 25, 2026. The Hub Group case, for shares bought between April 28, 2023 and May 11, 2026, concerns financial results, revenue recognition, and internal controls, and has a deadline of August 28, 2026. The Insulet action, for purchases between February 21, 2025 and May 26, 2026, involves manufacturing controls and procedures, with a deadline of August 31, 2026. Investors who suffered losses are encouraged to contact the firm to discuss their legal rights.

Insulet is seeing strong momentum for its Omnipod 5 automated insulin delivery system, with total company revenues growing 30.1% in constant currency in the first quarter of 2026, driven by Omnipod revenue growth of 33%. The global customer base expanded nearly 25% year over year, and Omnipod 5 is now available in 19 countries. Management raised its 2026 outlook, forecasting total company revenue growth of 21-23% and adjusted EPS growth of more than 25%. However, the company faces intensifying competition and macroeconomic pressures, including incremental raw material and shipping costs tied to the Middle East conflict, which could limit operating margin expansion. The stock has lost 46.9% over the past year, and the Zacks Consensus Estimate for 2026 EPS remains unchanged at $6.46.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Insulet Corporation and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Insulet securities between May 21, 2025 and May 26, 2026. The complaint claims that defendants made false and misleading statements about the company's business, operations, and compliance policies, specifically that manufacturing controls were defective, creating a foreseeable risk of safety violations or injury. Investors have until August 31, 2026 to seek lead plaintiff appointment. The law firm represents investors on a contingency fee basis.

The US FDA has classified a recall of certain Insulet Omnipod insulin pump systems as Class I, the most serious type. The recall affects specific lots of the Omnipod 5, Omnipod DASH, and Omnipod Eros devices. Insulet stated that pods in these lots may have a small tear in the cannula just above the skin, potentially causing insulin to leak and leading to under-delivery. As of May 20, Insulet reported 24 serious injuries and no deaths related to the issue.